03100nas a2200589   4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653002600111653002400137653001500161653001000176653002800186653001400214653002000228653001100248653002000259653001600279653001100295653002100306653002700327653002100354653001900375653001800394653001200412653000900424653001600433653002500449653001400474653001700488653002900505653001500534653002200549653003200571100001100603700001200614700001200626700001300638700001200651700001200663700001200675700001000687245018600697856007800883300001000961490000800971520151700979022001402496       2007                            d  c2007 Nov10aAdolescent10aAdult10aAged10aAged, 80 and over10aAntibodies, Bacterial10aAntigens, Bacterial10aBiomarkers10aChild10aCross-Sectional Studies10aCytokines10aDrug Monitoring10aFemale10aGlucocorticoids10aGlycolipids10aHumans10aImmunoglobulin M10aInflammation Mediators10aInterferon-gamma10aInterleukin-1010aInterleukin-410aleprosy10aMale10aMiddle Aged10aMycobacterium leprae10aNeopterin10aPrednisolone10aReceptors, Interleukin-610aSolubility10aTreatment Outcome10aTumor Necrosis Factor-alpha1 aIyer A1 aHatta M1 aUsman R1 aLuiten S1 aOskam L1 aFaber W1 aGeluk A1 aDas P00aSerum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219358/pdf/cei0150-0210.pdf  a210-60 v1503 a<p>Identifying pathogen and host-related laboratory parameters are essential for the early diagnosis of leprosy reactions. The present study aimed to clarify the validity of measuring the profiles of serum cytokines [interleukin (IL)-4, IL-6, IL-10, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha], the soluble IL-6 receptor (sIL-6R), soluble T cell (sCD27) and macrophage (neopterin) activation markers and Mycobacterium leprae-specific anti-PGL-I IgM antibodies in relation to the leprosy spectrum and reactions. Serum samples from 131 Indonesian leprosy patients (82 non-reactional leprosy patients and 49 reactional) and 112 healthy controls (HC) from the same endemic region were investigated. Forty-four (89.8%) of the reactional patients had erythema nodosum leprosum (ENL) while only five (10.2%) had reversal reaction (RR). Follow-up serum samples after corticosteroid treatment were also obtained from 17 of the patients with ENL and one with RR. A wide variability in cytokine levels was observed in the patient groups. However, IFN-gamma and sIL-6R were elevated significantly in ENL compared to non-ENL patients. Levels of IFN-gamma, TNF-alpha and sIL-6R declined significantly upon corticosteroid treatment of ENL. Thus, although the present study suggests limited applicability of serial measurement of IFN-gamma, TNF-alpha and sIL-6R in monitoring treatment efficacy of ENL, reactions it recommends a search for a wider panel of more disease-specific markers in future studies.</p>  a1365-2249